Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer-Reference-Cited by-同舟云学术

Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer

Published:2019-06 Issue: Volume:135 Page:170-177
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Martell K.^ORCID,Mendez L.C.^ORCID,Chung H.,Tseng C.L.,Zhang L.,Alayed Y.,Liu S.,Vesprini D.,Chu W.,Paudel M.,Cheung P.,Szumacher E.,Ravi A.^ORCID,Loblaw A.^ORCID,Morton G.^ORCID

Funder

University of Toronto

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference39 articles.

1. Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States;Barocas;J Urol,2015

2. US preventive services task force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses;Gejerman;Investig Clin Urol,2017

3. Prostate cancer screening and the goldilocks principle: How much is just right?;Faiena;J Clin Oncol,2018

4. The uptake of active surveillance for the management of prostate cancer: a population-based analysis;Richard;Can Urol Assoc J,2016

5. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance;Porten;J Clin Oncol,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of Gleason Pattern 4 at MRI-Guided Biopsy to Predict Adverse Pathology at Radical Prostatectomy in Intermediate-Risk Prostate Cancer Patients;Cancers;2023-11-17

2. Estimated absolute percentage of biopsied tissue positive for Gleason pattern 4 (eAPP4) in low dose rate prostate brachytherapy: Evaluation of prognostic utility in a large cohort;Radiotherapy and Oncology;2023-11

3. Absolute Percentage of Pattern 4 Disease as a Prognostic Measure for Intermediate-risk Prostate Cancer Treated with Stereotactic Body Radiotherapy;Clinical Oncology;2022-09

4. Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial;Pathology;2022-02

5. Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis;Clinical Oncology;2022-01